Aimmune Therapeutics (AIMT) Releases Earnings Results, Beats Estimates By $0.03 EPS

Share on StockTwits

Aimmune Therapeutics (NASDAQ:AIMT) issued its earnings results on Thursday. The biotechnology company reported ($0.89) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.92) by $0.03, Briefing.com reports.

Shares of AIMT stock opened at $30.29 on Friday. The company has a market cap of $1.88 billion, a P/E ratio of -11.61 and a beta of -0.10. Aimmune Therapeutics has a 52-week low of $24.56 and a 52-week high of $42.00.

A number of equities analysts have recently commented on AIMT shares. ValuEngine lowered shares of Aimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 7th. Cantor Fitzgerald set a $62.00 target price on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Monday, October 15th. BidaskClub lowered shares of Aimmune Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 11th. Stifel Nicolaus started coverage on shares of Aimmune Therapeutics in a research report on Thursday, September 13th. They set a “hold” rating and a $33.00 target price on the stock. Finally, Roth Capital set a $80.00 target price on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, October 9th. Three equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $50.70.

COPYRIGHT VIOLATION NOTICE: “Aimmune Therapeutics (AIMT) Releases Earnings Results, Beats Estimates By $0.03 EPS” was first reported by BBNS and is the sole property of of BBNS. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://baseballnewssource.com/2018/11/10/aimmune-therapeutics-aimt-releases-earnings-results-beats-estimates-by-0-03-eps/2972879.html.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

Read More: Diversification

Earnings History for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.